Back to top
more

Sutro Biopharma (STRO)

(Real Time Quote from BATS)

$3.44 USD

3.44
521,199

-0.03 (-0.87%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $3.43 -0.01 (-0.29%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Sutro Biopharma (STRO) delivered earnings and revenue surprises of 151.22% and 834.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Sutro Biopharma (STRO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 8.51% and 54.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Why Sutro Biopharma (STRO) Might Surprise This Earnings Season

by Zacks Equity Research

Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 12.33% and 0.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 19.23% and 80.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -31.82% and 44.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Sutro Biopharma, Inc. (STRO) Rating Upgrade to Buy

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Stoke Therapeutics, Inc. (STOK) Surges 6.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 8.43% and 11.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 8% and 3.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

IDEAYA Biosciences, Inc. (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adma Biologics (ADMA) delivered earnings and revenue surprises of 14.29% and 1.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 214%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 213.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -146.67% and 121.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of 21.11% and 18.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Believe Sutro Biopharma, Inc. (STRO) Could Rally 326%: Here's is How to Trade

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 326% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Sutro Biopharma, Inc. (STRO) Have the Potential to Rally 293% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 293.4% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

bluebird's (BLUE) Gene Therapy Gets FDA Nod for CALD

by Zacks Equity Research

bluebird's (BLUE) Syskona (eli-cel) gets FDA approval for early, active cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age.